Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01125800 : A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
PhasePhase 1/Phase 2
AgesMin: 12 Months Max: 18 Years
Eligibility
Inclusion Criteria:

- Phase I - Patients aged ?12 months and <18 years, Phase II - Patients ?12 months

- Phase I - Histologically confirmed diagnosis of medulloblastoma, rhabdomyosarcoma,
neuroblastoma, hepatoblastoma, high grade glioma, or osteosarcoma, that has
progressed despite treatment with standard therapies, or for which no standard
treatments are available (patients with brainstem gliomas are excluded). Phase II -
Histologically confirmed diagnosis of recurrent or relapsed medulloblastoma with at
least one measurable lesion.

- Performance Status: Karnofsky ?60% for patients >10 yrs, Lansky ?50 for patients less
than or equal to 10 yrs

- Protocol-defined renal , liver and bone marrow function

- Negative pregnancy test before starting study treatment. If of child bearing
potential must use 'highly effective' methods of contraception.

- All patients must consent to provide a tumor sample

Exclusion Criteria:

- Systemic anti-cancer treatment within 2 weeks prior to first dose (6 weeks for
nitrosourea, mitomycin and monoclonal antibodies).

- Focal radiotherapy within 4 weeks prior to first dose, or full spinal radiotherapy
within 3 months of first dose.

- Unresolved toxicity greater than CTCAE grade 1 from previous anti-cancer therapy or
radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia or other
specifications in the eligibility criteria for this study), or incomplete recovery
from previous surgery, unless agreed by Novartis and the Principal Investigator (PI)
and documented.

- Major surgery, serious illness or traumatic injury within 2 weeks of starting study
therapy. Patients anticipated to require major surgery within the first 2 cycles of
treatment.

- Patients requiring a nasogastric tube for drug administration (G-tubes are permitted)

- Impaired cardiac function

- Pregnant or breast-feeding females

- Impairment of gastrointestinal (GI) function or GI disease

Other protocol-defined inclusion/exclusion criteria may apply
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01125800      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740